Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The generic injectables market is experiencing significant growth and evolution driven by various factors such as increasing demand for affordable healthcare solutions, patent expirations of branded drugs, and growing prevalence of chronic diseases requiring injectable therapies. One prominent trend in the generic injectables market is the rising adoption of biosimilar injectables, which are generic versions of biologic drugs that have lost patent protection. With the growing acceptance of biosimilars as safe and effective alternatives to branded biologic drugs, healthcare providers and payers are increasingly embracing biosimilar injectables to reduce healthcare costs, expand patient access to essential therapies, and promote competition in the biologics market. This trend towards biosimilar adoption is driving innovation in biosimilar development, manufacturing, and regulatory pathways, as well as strategic partnerships and collaborations between generic drug manufacturers and biotechnology companies to bring biosimilar injectables to market.
Moreover, there is a growing demand for complex generic injectables, including sterile injectable drugs, oncology drugs, and injectable antibiotics, as well as niche and specialty injectables for rare diseases and specialty indications. With the increasing complexity and specialization of injectable drug formulations, generic drug manufacturers are investing in research and development to develop and commercialize complex generic injectables that offer therapeutic equivalence to branded drugs while addressing specific patient needs and preferences. This trend towards complex generics is driving innovation in formulation development, drug delivery technologies, and manufacturing processes to overcome technical and regulatory challenges associated with complex injectable drug products.
Additionally, the generic injectables market is witnessing increasing consolidation and vertical integration among generic drug manufacturers, contract development and manufacturing organizations (CDMOs), and pharmaceutical wholesalers to strengthen market presence, enhance manufacturing capabilities, and improve supply chain efficiency. Large generic drug manufacturers are acquiring or forming strategic partnerships with smaller specialty injectables manufacturers and CDMOs to expand their product portfolios, access specialized manufacturing capabilities, and increase market share in key therapeutic areas such as oncology, neurology, and critical care. This trend towards consolidation and vertical integration is driving economies of scale, operational synergies, and strategic alliances across the generic injectables value chain, enabling companies to optimize resources and compete more effectively in the global market.
Furthermore, there is a growing focus on quality and regulatory compliance in the generic injectables market, driven by increasing scrutiny from regulatory agencies and healthcare authorities worldwide. With the rising incidence of drug shortages, product recalls, and quality issues associated with generic injectables, regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are implementing stricter standards and requirements for manufacturing, quality control, and supply chain management of generic injectables. This trend towards regulatory compliance is driving investments in quality assurance, quality control, and good manufacturing practices (GMP) to ensure product quality, safety, and efficacy, as well as supply chain resilience and continuity.
Moreover, the generic injectables market is witnessing growing demand for ready-to-use injectable products and prefilled syringes to simplify medication administration, reduce medication errors, and improve patient convenience and compliance. Healthcare providers and patients are increasingly opting for prefilled syringes and ready-to-use injectables that require minimal preparation and handling, eliminating the need for manual reconstitution or dilution of injectable drugs and reducing the risk of dosage errors, contamination, and needlestick injuries. This trend towards prefilled syringes and ready-to-use injectables is driving innovation in packaging, drug delivery devices, and manufacturing processes to meet the growing demand for convenient and user-friendly injectable products in healthcare settings.
Lastly, the generic injectables market is experiencing significant growth in emerging markets, driven by increasing healthcare spending, expanding access to essential medicines, and rising demand for affordable injectable therapies in developing countries. Emerging economies in Asia, Latin America, and Africa are witnessing rapid urbanization, demographic changes, and epidemiological transitions, leading to a growing burden of chronic diseases and infectious diseases that require injectable treatments. This has created opportunities for generic injectables manufacturers to expand their presence in these markets by offering affordable, high-quality injectable drugs that meet the needs and preferences of local healthcare systems and patient populations.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Opportunities | joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments |
Generic Injectables Market Highlights:
Generic Injectables Market Overview
Generic Injectables Market Size was valued at USD 19.70 Billion in 2023. The Global Generic Injectables industry is projected to grow from USD 21.69 Billion in 2024 to USD 47.69 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.35% during the forecast period (2024 - 2032).
Lower centre around upgradation of the medical care framework and nature of the administrations in a couple of immature nations could present critical difficulties to the conventional injectable designers.
But, with undertakings zeroing in on attempting to be more ready for future necessities and guaranteeing a steadier stockpile chain will guarantee market's solid development in the following couple of years. Significant designers of conventional injectables are attempting to redirect their money in-stream generally on thorough exploration exercises, which centre around creating and commercializing inventive medication conveyance frameworks.
Blossoming old patient base, rising weight of different wellbeing problems, including heart, malignant growth, and diabetes, joined with the increased utilization of conventional injectables overall will be significant for the market in ensuing years.
Government bodies alongside the monetary specialists across various nations are setting new projects as well as monetary plans for the nonexclusive injectables market engineers. The monetary guides given to the endeavors to improve their business discernment will end up being extraordinary open doors later on.
Based on area, the nonexclusive injectables market is sectioned into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-portioned into North America and Latin America. The North American district is additionally sectioned into the US and Canada. The European area is isolated into two, specifically, Western Europe and Eastern Europe.
Western Europe is additionally grouped into Germany, Italy, France, the UK, Spain, and the remainder of Western Europe. The Asia-Pacific locale is sub-fragmented into Japan, China, India, Australia, South Korea, and the remainder of Asia-Pacific. The nonexclusive injectables market in the Middle East and Africa has been fragmented into the Middle East and Africa.
Generic Injectables Market Segmentation
The generic injectables market is segmented on the basis of product type, container, application, distribution channel, and end user.
The market, by product type is categorised into monoclonal antibodies, cytokines, insulin, vaccines, and others.
On the basis of container, the market is segmented into vials, ampoules, premix, and prefilled syringes.
Based on application, the market of generic injectables is segmented oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular, and others.
The market, by distribution channel is categorised into hospital pharmacy, retail pharmacy, drug stores, and online prescription stores.
On the basis of region, the generic injectables market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The market of generic injectables in the Middle East and Africa has been segmented into the Middle East and Africa.
Global Generic injectables Market Share (%), by Region
Sources: Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, National Institutes of Health
Generic Injectables Market Regional Analysis
It is projected that the Americas dominated the generic injectables market owing to the growth of the market in the North American region. This is largely attributed to the factors such as an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs. Even though the generic injectable industry has operations across the globe, majority of largest manufacturers produce a large volume of generic injectable in the U.S. Moreover, in the U.S. over 70% of hospital patients receive generic injectable drugs, which is further pushing the demand for generic injectable in North America.
Europe is currently holding a considerable amount of market share in the generic injectables market owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. For instance, in June 2017, Baxter signed an agreement with Dorizoe for life sciences company manufacturing generic sterile injectable. This alliance is anticipated to develop more than 20 generic injectable products including cardiovascular and oncolytic medicines.
Asia-Pacific was projected to be the fastest growing region for the market of generic injectables. This owes to the infrastructural development and increase in outsourcing of research activities to the contract research organizations (CROs) at relatively low cost in this region. For example, the Sun Pharma’s acquisition of Pharmalucence in 2014 that resulted in benchmarking sales of generic sterile injectable.
The Middle East and Africa holds the least share in the generic injectables market due to the presence of economically diverse countries, and less initiatives taken by the government.
Major players in the Generic Injectables Market
- Novartis AG (Sandoz International GmbH)
- Baxter
- Fresenius SE & Co. KGaA
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals plc
- Sanofi
- Biocon
- Reddy’s Laboratories
- Aurobindo Pharma
- Zydus Cadila
- GlaxoSmithKline plc
- AstraZeneca plc.
Recent Developments
November 2023: Teva Pharmaceutical Industries Ltd. announces that it has received FDA approval for its new generic version of Trulicity (dulaglutide), a GLP-1 receptor agonist for the treatment of type 2 diabetes. Trulicity is a long-acting injectable medication that is administered once a week.Mylan N.V. announces that it has launched a new generic version of Humira (adalimumab), a TNF inhibitor for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Humira is a biologic drug that is administered as an injection every two weeks.Sandoz AG announces that it has launched a new generic version of Neulasta (pegfilgrastim), a G-CSF for the treatment of neutropenia. Neulasta is a biosimilar drug that is administered as an injection once a day.
September 2023: Several companies announce new partnerships to develop and commercialize new generic injectables. These partnerships aim to develop new therapies for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases.A new study published in the journal Clinical Pharmacology and Therapeutics finds that a new type of generic injectable is effective in treating patients with advanced melanoma. The study found that the new generic injectable was as effective as the brand-name drug and had a lower side effect profile.Another study published in the journal Cancer found that a new type of generic injectable can be used to treat patients with type 1 diabetes. The study found that the new generic injectable was effective in producing insulin in the body and reversing the symptoms of diabetes.
February 2022: Cosette Pharmaceuticals Inc., a drug firm has sent off Prochlorperazine Edisylate infusion, which is the nonexclusive identical to the Compazine Injection 10mg/2ml. Prochlorperazine Edisylate helps control serious queasiness as well as retching. Prochlorperazine Edisylate likewise helps treating schizophrenia.
Generic Injectables Product type Outlook
- Monoclonal antibodies
- Cytokines
- Insulin
- Vaccines
- Others
Generic Injectables Container Outlook
- Vials
- Ampoules
- Premix
- Prefilled syringes
Generic Injectables Application Outlook
- Oncology
- Anaesthesia
- Anti-infectives
- Parenteral nutrition
- Cardiovascular
- Others
Generic Injectables Distribution Channel Outlook
- Hospital pharmacy
- Retail pharmacy
- Drug stores
- Online prescription stores
- Others
Generic Injectables Region Outlook
Americas
- North America
- US
- Canada
- Latin America
Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
The Middle East & Africa
-
Middle East
-
Africa
Intended Audience
- Pharmaceutical & Biopharmaceutical companies
- Biotechnological companies
- Government institutions
- Research and Development (R&D) companies
- Medical research laboratories
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
